GSK plc (NYSE:GSK) Shares Bought by Thomasville National Bank

Thomasville National Bank lifted its position in shares of GSK plc (NYSE:GSK - Free Report) by 3.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 491,441 shares of the pharmaceutical company's stock after buying an additional 16,057 shares during the period. GSK makes up approximately 1.2% of Thomasville National Bank's portfolio, making the stock its 29th largest position. Thomasville National Bank's holdings in GSK were worth $16,621,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in GSK. Sunbelt Securities Inc. lifted its position in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock worth $29,000 after purchasing an additional 302 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in GSK by 9.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company's stock valued at $137,000 after buying an additional 303 shares in the last quarter. Mesirow Financial Investment Management Inc. lifted its holdings in GSK by 2.0% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company's stock worth $682,000 after buying an additional 323 shares during the last quarter. Rehmann Capital Advisory Group boosted its position in shares of GSK by 6.3% during the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company's stock worth $232,000 after acquiring an additional 332 shares in the last quarter. Finally, Investment Partners Asset Management Inc. increased its holdings in shares of GSK by 2.3% in the 3rd quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company's stock valued at $636,000 after acquiring an additional 344 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a report on Monday. Deutsche Bank Aktiengesellschaft cut shares of GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Jefferies Financial Group lowered shares of GSK from a "buy" rating to a "hold" rating and cut their price target for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Guggenheim downgraded shares of GSK from a "buy" rating to a "neutral" rating in a research note on Thursday, October 31st. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to MarketBeat.com, GSK has a consensus rating of "Moderate Buy" and a consensus target price of $43.25.

GSK Stock Performance

NYSE:GSK traded down $0.38 during trading hours on Monday, reaching $32.71. 4,673,691 shares of the company's stock were exchanged, compared to its average volume of 3,213,207. GSK plc has a 1-year low of $32.55 and a 1-year high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $67.79 billion, a price-to-earnings ratio of 21.24, a P/E/G ratio of 1.52 and a beta of 0.63. The company has a 50-day moving average of $34.38 and a 200 day moving average of $38.17.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were paid a dividend of $0.3928 per share. The ex-dividend date was Friday, November 15th. This is an increase from GSK's previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a yield of 4.80%. GSK's dividend payout ratio is currently 95.45%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.